ClinicalTrials.gg

Program

Rivaroxaban

Also written as “Rivaroxaban (Xarelto, BAY59-7939)”, “Xarelto (Rivaroxaban, BAY59-7939)” and “Rivaroxaban (BAY59-7939)”.

Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Venous Thrombosis · Thrombosis · Pulmonary Embolism, led by 9 companies.

Furthest: phase 4, since May 24, 200671 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer450 open or runningphase 3since May 24, 2006May 24, 2006none ahead
Johnson & Johnson170 open or runningphase 4since Sep 11, 2015Nov 21, 2006none ahead
Dexa Medica Group20 open or runningphase 1since Aug 14, 2024Aug 14, 2024none ahead
Pharmtechnology20 open or runningphase 1since Jan 25, 2021Jan 25, 2021none ahead
ECRI bv10 open or runningphase 3since Jun 24, 2016Jun 24, 2016none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Mar 1, 2017Mar 1, 2017none ahead
Merck10 open or runningphase 1since Jun 3, 2011Jun 3, 2011none ahead
pharmevo-pvt-ltd10 open or runningphase 4since Dec 8, 2016Dec 8, 2016none ahead
Yuhan10 open or runningphase 1since Nov 10, 2021Nov 10, 2021none ahead

Also a collaborator on its studies: parexel, pt-equilab-international and cardialysis-bv.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Feb 23, 2007.

  1. Sep 4, 2015Phase 2 study in ThromboembolismBayer · NCT02564718 · 10 enrolled · Austria, France, Germany and more
  2. Sep 5, 2015Phase 3 study in Transcatheter Aortic Valve ReplacementBayer · NCT02556203 · 1,653 enrolled · United States, Austria, Belgium and more
  3. Sep 11, 2015Phase 4 study in Pulmonary EmbolismJohnson & Johnson · NCT02584660 · 114 enrolled · United States
  4. Sep 18, 2015Phase 3 study in NeoplasmsJohnson & Johnson · NCT02555878 · 841 enrolled · United States, Belgium, Brazil and more
  5. Jun 24, 2016ECRI bv's first study: phase 3 study in Aortic Valve StenosisNew to ECRI bvECRI bv · NCT02833948 · 231 enrolled · United States, Canada, Denmark and more
  6. Jul 25, 2016Phase 3 study in ThrombosisJohnson & Johnson · NCT02846532 · 112 enrolled · United States, Argentina, Belgium and more
  7. Dec 8, 2016pharmevo-pvt-ltd's first study: phase 4 study in Mitral Valve StenosisNew to pharmevo-pvt-ltdpharmevo-pvt-ltd · NCT03673605 · Pakistan
  8. Mar 1, 2017Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT03071380 · 24 enrolled · Egypt
  9. Aug 10, 2020Phase 3 study in COVID-19Johnson & Johnson · NCT04508023 · 1,284 enrolled · United States
  10. Jan 19, 20212 phase 1 studiesBayer · NCT04727021, NCT04720092
  11. Jan 25, 2021Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04729998 · 34 enrolled · Russian Federation
  12. Feb 10, 2021Phase 1 study in BioequivalencePharmtechnology · NCT04753489 · 34 enrolled · Russian Federation
  13. Nov 10, 2021Yuhan's first study: phase 1 study in Embolism and ThrombosisNew to YuhanYuhan · NCT05128591 · 38 enrolled · Korea, Republic of
  14. Aug 14, 2024Dexa Medica Group's first studies: 2 phase 1 studies in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT06558058, NCT06558045

TargetBeta

F10 →read by rule
“Coagulation factor X inhibitor”ChEMBL 37, by rule

Other programs on F10

ProgramCompanyFurthest phaseStudies
apixabanruleBristol-Myers Squibbphase 444
emicizumabruleHoffmann-La Rochephase 413
Factor Xrulekedrion-s-p-aphase 31

Studies

The newest 60 of 71 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06558058Healthy · Indonesia1CompletedDexa Medica GroupJun 16, 202328
NCT06558045Healthy · Indonesia1CompletedDexa Medica GroupJul 18, 202326
NCT05128591Embolism and Thrombosis · Korea, Republic of1CompletedYuhanDec 31, 202138
NCT04753489Bioequivalence · Russian Federation1UNKNOWNPharmtechnologyMar 1, 202134
NCT04729998Bioequivalence · Russian Federation1UNKNOWNPharmtechnologyFeb 15, 202134
NCT04720092Thromboembolism · Germany1CompletedBayerAug 28, 201730
NCT04727021Healthy Volunteers · Germany1CompletedBayerSep 4, 201730
NCT04508023COVID-19 · United States3TerminatedJohnson & JohnsonJun 1, 20221,284
NCT03071380Healthy · Egypt1CompletedGenuine Research Center, EgyptFeb 201524
NCT03673605Mitral Valve Stenosis · Pakistan4Withdrawnpharmevo-pvt-ltdOct 30, 20170
NCT02846532Thrombosis · United States, Argentina, Belgium and more3CompletedJohnson & JohnsonJul 16, 2020112
NCT02833948Aortic Valve Stenosis · United States, Canada, Denmark and more3CompletedECRI bvDec 2018231
NCT02555878Neoplasms · United States, Belgium, Brazil and more3CompletedJohnson & JohnsonAug 24, 2018841
NCT02584660Pulmonary Embolism · United States4CompletedJohnson & JohnsonMar 22, 2017114
NCT02556203Transcatheter Aortic Valve Replacement · United States, Austria, Belgium and more3TerminatedBayerNov 27, 20181,653
NCT02564718Thromboembolism · Austria, France, Germany and more2CompletedBayerDec 18, 201710
NCT02537457Embolism · Japan1CompletedBayerMar 201440
NCT02537405Embolism · Japan1CompletedBayerMar 201440
NCT02561923Healthy · United States1CompletedJohnson & JohnsonJun 17, 2016158
NCT02504216Peripheral Arterial Disease · United States, Argentina, Austria and more3CompletedBayerNov 27, 20196,564
NCT02497716Thrombosis · United States, Belgium, Canada and more1CompletedBayerMay 22, 201847
NCT02367027Pharmacokinetics · Germany1CompletedBayerApr 201518
NCT02313909Stroke · United States, Argentina, Australia and more3TerminatedBayerFeb 15, 20187,213
NCT02309411Venous Thromboembolism · United States, Australia, Austria and more2CompletedBayerApr 5, 201746
NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more2CompletedJohnson & JohnsonOct 14, 20163,037
NCT02289703Kidney Failure, Chronic · United States1CompletedJohnson & JohnsonMar 201516
NCT02234843Venous Thromboembolism · United States, Argentina, Australia and more3CompletedBayerJan 30, 2019500
NCT02111564Heart Failure · United States, Argentina, Australia and more3CompletedJohnson & JohnsonMar 6, 201812,024
NCT02064439Pulmonary Embolism · United States, Australia, Austria and more3CompletedBayerSep 22, 20163,365
NCT01877915Heart Failure · United States, Argentina, Australia and more3CompletedJohnson & JohnsonApr 19, 20185,081
NCT01853800Biological Availability · Germany1CompletedBayerJul 201314
NCT01839357Atrial Fibrillation · Bulgaria, France, Germany and more3CompletedBayerNov 201460
NCT01830543Atrial Fibrillation · United States, Argentina, Australia and more3CompletedJohnson & JohnsonJul 28, 20162,124
NCT01776424Coronary Artery Disease · United States, Argentina, Australia and more3CompletedBayerJul 21, 201727,395
NCT01729871Atrial Fibrillation · United States, Belgium, France and more3CompletedJohnson & JohnsonOct 2014253
NCT01684423Venous Thrombosis · United States, Australia, Austria and more2CompletedBayerSep 1, 201664
NCT01674647Atrial Fibrillation · United States, Belgium, Brazil and more3CompletedBayerJan 20141,504
NCT01516840Venous Thrombosis · Japan3CompletedBayerDec 201360
NCT01516814Pulmonary Embolism · Japan3CompletedBayerOct 201340
NCT01507051Venous Thrombosis · Germany1CompletedBayerNov 200996
NCT01464450Pharmacokinetics · United States1CompletedJohnson & JohnsonDec 201155
NCT01436526Therapeutic Equivalency · Germany1CompletedBayerSep 200928
NCT01442792Cardiovascular Diseases · Belgium, Netherlands2CompletedBayerJan 29, 2013108
NCT01379300Thrombosis1CompletedMerckDec 201142
NCT01309438Renal Insufficiency · United States1CompletedJohnson & JohnsonMar 201229
NCT01206972Venous Thromboembolism · Japan3CompletedBayerMay 2011302
NCT01205932Venous Thromboembolism · Japan3CompletedBayerJun 2011402
NCT01145859Venous Thrombosis · United States, Australia, Austria and more1CompletedBayerJul 201559
NCT01094886Arthritis · United States3CompletedJohnson & JohnsonDec 201056
NCT00973245Atrial Fibrillation · Japan2CompletedBayer102
NCT00973323Atrial Fibrillation · Japan2CompletedBayer100
NCT00839826Thromboembolism · Austria, Belgium, Denmark and more2CompletedBayerNov 2003641
NCT00839163Venous Thrombosis · Australia, Austria, Belgium and more2CompletedBayerOct 2005613
NCT00809965Acute Coronary Syndrome · United States, Argentina, Australia and more3CompletedJohnson & JohnsonSep 201115,526
NCT00786422Venous Thrombosis · Australia, Austria, Brazil and more2CompletedBayerMay 201125
NCT00779064Atrial Fibrillation · Japan2CompletedBayerJun 200536
NCT00571649Venous Thromboembolism · United States, Argentina, Australia and more3CompletedBayerAug 20108,101
NCT00494871Atrial Fibrillation · Japan3CompletedBayerDec 20091,280
NCT00440193Venous Thrombosis · United States, Australia, Austria and more3CompletedBayerApr 20103,449
NCT00439777Pulmonary Embolism · United States, Andorra, Australia and more3CompletedBayerSep 20114,833

How it is read

Names in the registry

  • “Rivaroxaban (Xarelto, BAY59-7939)”, 46 entries
  • “Rivaroxaban”, 14 entries
  • “Xarelto (Rivaroxaban, BAY59-7939)”, 13 entries
  • “Rivaroxaban (BAY59-7939)”, 13 entries
  • “Rivaroxaban, (BAY59-7939)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.